%0 Journal Article
%T The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis
%A Ji-Feng Wu
%A Jian-Jun Zhou
%A Li-Hui Hu
%A Meng-Li Wen
%A Xin-Ai Li
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S200601
%X Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemotherapy for previously untreated ED-SCLC. While, the efficacies of these amrubicin-based regimens are unsatisfactory
%K small-cell lung cancer
%K extensive-disease
%K amrubicin
%K meta-analysis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611712/